NCT06665386 Prognostic Biomarkers for Selective Intra-Arterial Cooling Infusion Combined with Endovascular Thrombectomy in Acute Ischemic Stroke Based on Proteomics and Metabolomics.
| NCT ID | NCT06665386 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Capital Medical University |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 258 participants |
| Start Date | 2024-10-27 |
| Primary Completion | 2025-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 258 participants in total. It began in 2024-10-27 with a primary completion date of 2025-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Endovascular Thrombectomy has emerged as a pivotal treatment modality for acute ischemic stroke. However, despite successful thrombus removal, a substantial proportion of patients still experience poor outcomes. Selective intra-arterial cooling has shown promise in decelerating stroke progression and providing neuroprotection. This study aims to identify biomarkers associated with the combination of selective intra-arterial cooling infusion and endovascular thrombectomy in the treatment of ischemic stroke by integrating proteomics and metabolomics data. Our study is based on the multicenter RCT study "Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke." All samples were derived from this experiment. Our objective is to elucidate the molecular mechanisms underlying the prognostic impact of this combined therapeutic approach, providing insights to optimize stroke treatment strategies.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 and ≤80. * Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA. * NIHSS score obtained prior to randomization ≥6 and ≤25. * Modified Rankin Scale ≤ 1 prior to qualifying stroke. * Arterial puncture performed within 24 hours from symptom onset or LKW. * For the patients with symptom onset within 6 hours, the ASPECT score ≥6; for the patientswith onset within 6-24 hours, the therapy should meet the imaging criteria of DAWN or DEFUSE-3 trial. * Patient/Legally Authorized Representative has signed the Informed Consent Form. Exclusion Criteria: * Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes. * Baseline CT/MRI confirms the presence of arterial dissection. * Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy. * Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics. * Severe infection (e.g. sepsis) or multiple organ failure. * Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \> 3. Patients on factor Xa inhibitor for 48 hours ago must have a normal APTT. * Baseline platelet count \<50 × 109/L. * Blood glucose concentration\<50 mg/dL (2.7mmol/L) or \>400 mg/dL (22.2mmol/L). * Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\>185 mmHg or diastolic blood pressure\>110mmHg). * Previous NHYA\>1. * Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery. * Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate \<30 ml/min or serum creatinine \>220 mmol/L (2.5mg/dl). * Known intracranial aneurysm, and cerebral arteriovenous malformation. * Malignant brain tumor or CNS infection. * Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness) * Female who is pregnant or lactating at time of admission. * Anticipated life expectancy \<6 months. * Current participation in another investigational drug or device study. * For other reasons, the responsible clinicians believe that the patient is not suitable for continued treatment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06665386 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06665386 currently recruiting?
Yes, NCT06665386 is actively recruiting participants. Contact the research team at chenxi00cx@126.com for enrollment information.
Where is the NCT06665386 trial being conducted?
This trial is being conducted at Dalian, China.
Who is sponsoring the NCT06665386 clinical trial?
NCT06665386 is sponsored by Capital Medical University. The trial plans to enroll 258 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.